Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Trial Profile

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary) ; Ponatinib (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Nov 2017 New trial record
    • 07 Nov 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top